AUM, FANA and RNA Silencing

AUM LifeTech is a Philadelphia based biotechnology company with a revolutionary nucleic acids platform in the gene silencing and regulation space. AUM’s FANA RNA silencing and regulation technology can be used to very efficiently target a variety of RNA modalities like – mRNA, microRNA and long non-coding RNA. FANA technology can be used for discovery, translational and potentially for therapeutic development. AUM has established several key collaborations and is currently in discovery and pre-clinical stages of therapeutic development for a wide spectrum of genetic diseases. In addition Considering the success and versatility of our next generation RNA silencing and regulation platform AUM is now making the technology available to biomedical researchers across the globe.

Tech Image

The sequencing of the first human genome took about 13 years and US$ 3 billion. Today an almost similar task can be done in less than 24 hours for about US$ 1000. The scientific community is generating a plethora of genetic information and is always looking to understand the functions of both coding and non-coding RNA with a hope to
use this information to develop therapeutics. There are many conventional technologies available to dissect and explore this information but most of them are not translational. There are many obstacles (biggest of them being delivery) with the conventional RNA silencing and regulation technologies. Further, researchers spend a lot of time to identify the perfect RNA target (in discovery phase) but then resort to small molecules and biologics when they translate to pre-clinical or clinical development. Many times this changes the dynamics and end in failures. Our goal is to successfully address these challenges with our next generation FANA RNA silencing and regulation technology. Most importantly, bring the discoveries to clinic as soon as we can.

Tech Image

With the expanding advances in genetic regulatory networks researchers are now able to efficiently link diseases/disorders with certain genes. The advances in sequencing technologies have enabled us to make much more sense of this plethora of genetic information. This has enabled to further establish gene function that has the potential to treat and/or prevent human disease. Further, these advancements have created a huge demand for a technology that can be used to find research and clinical solutions using this genetic information. To this end, AUM LifeTech aims to provide innovative, potent and cost effective genomics solutions in the area of basic biomedical research, clinical diagnostics and therapeutics.

Tech Image